JP2023525085A5 - - Google Patents

Info

Publication number
JP2023525085A5
JP2023525085A5 JP2022568397A JP2022568397A JP2023525085A5 JP 2023525085 A5 JP2023525085 A5 JP 2023525085A5 JP 2022568397 A JP2022568397 A JP 2022568397A JP 2022568397 A JP2022568397 A JP 2022568397A JP 2023525085 A5 JP2023525085 A5 JP 2023525085A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
amino acid
antibody
product according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525085A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/090073 external-priority patent/WO2021226883A1/en
Application filed filed Critical
Priority claimed from PCT/CN2021/093511 external-priority patent/WO2021228178A1/en
Publication of JP2023525085A publication Critical patent/JP2023525085A/ja
Publication of JP2023525085A5 publication Critical patent/JP2023525085A5/ja
Pending legal-status Critical Current

Links

JP2022568397A 2020-05-13 2021-05-13 がんを治療するための組成物および方法 Pending JP2023525085A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/090073 2020-05-13
PCT/CN2020/090073 WO2021226883A1 (en) 2020-05-13 2020-05-13 Compositions and methods for treating cancer submission of sequence listing on ascii text file
CNPCT/CN2020/094278 2020-06-04
PCT/CN2020/094278 WO2021227156A1 (en) 2020-05-13 2020-06-04 Compositions and methods for treating cancer
PCT/CN2020/115795 WO2021227326A1 (en) 2020-05-13 2020-09-17 Compositions and methods for treating cancer
CNPCT/CN2020/115795 2020-09-17
PCT/CN2021/093511 WO2021228178A1 (en) 2020-05-13 2021-05-13 Compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2023525085A JP2023525085A (ja) 2023-06-14
JP2023525085A5 true JP2023525085A5 (https=) 2024-05-20

Family

ID=78525910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568397A Pending JP2023525085A (ja) 2020-05-13 2021-05-13 がんを治療するための組成物および方法

Country Status (8)

Country Link
US (1) US20230133118A1 (https=)
EP (2) EP4559477A3 (https=)
JP (1) JP2023525085A (https=)
CN (1) CN115768525A (https=)
AU (1) AU2021271971A1 (https=)
CA (1) CA3177717A1 (https=)
TW (1) TW202200622A (https=)
WO (1) WO2021228178A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2022212286A1 (en) * 2021-03-28 2022-10-06 Peter Peizhi Luo Methods for treating cancer using anti-ctla4 antibodies
GB202210957D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
JP2025531229A (ja) * 2022-09-16 2025-09-19 オンコシーフォー、インク. 腺様嚢胞がんを処置するための抗ctla-4抗体の使用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69233408T2 (de) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド 免疫療法のctla−4結合ペプチド
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
ATE411054T1 (de) 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006055697A2 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
JP2008542354A (ja) 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるerbB2阻害剤と他の治療薬の併用
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
JP5256042B2 (ja) 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2696460A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
AU2014364593A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
WO2017140826A1 (en) * 2016-02-18 2017-08-24 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
CN114456269A (zh) 2016-09-21 2022-05-10 基石药业(苏州)有限公司 一种新的pd-1单克隆抗体
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same

Similar Documents

Publication Publication Date Title
JP2023525085A5 (https=)
TWI795347B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
JP7438947B2 (ja) Iapアンタゴニスト及び抗pd-1分子による併用抗癌療法
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP2021514969A5 (https=)
TW201808330A (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
CN102711825A (zh) 用于施用EpCAMxCD3双特异性抗体的给药方案
JP7193628B2 (ja) 低adcc/cdc機能性モノクローナル抗体、及びその調製方法と使用
RS64388B1 (sr) Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma
WO2020180898A1 (en) Methods and compositions for treating cancer
WO2019090330A1 (en) Methods of treating a tumor
Santos et al. Immunotherapy in gastric cancer—A systematic review
JP2022527177A (ja) 腫瘍を処置する方法
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
WO2022122765A2 (en) Antibody and taxane combination therapy
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
KR20230056761A (ko) Pd-1 저해제의 투여에 의한 암 치료 방법
CN121866269A (zh) 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法
JP2025539459A (ja) 癌におけるネオアジュバント処置のための組成物および方法
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
JP2024144605A (ja) がんを処置するための方法および組成物
WO2024149224A1 (zh) Ccr8抗体的应用
WO2026082153A1 (zh) 抗Nectin-4抗体药物偶联物治疗肿瘤的用途
RU2806210C2 (ru) Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого